Carvedilol — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.1-0.2 mg/kg initially, titrate up to 0.4-1.0 mg/kg	q12h	Duration: Long-term, titrate to effect Notes: Start at low dose and increase gradually every 2 weeks to reduce risk of hypotension and worsening heart failure. Monitor heart rate and blood pressure.
Cat	PO	0.1-0.2 mg/kg initially, titrate up to 0.5-1.0 mg/kg	q12h	Duration: Long-term, titrate to effect Notes: Use cautiously in cats with asthma or bronchospasm. Monitor for bradycardia and hypotension.
Horse	PO	0.1-0.2 mg/kg	q12h	Duration: Not established Notes: Limited data; use with caution and monitor cardiovascular parameters.
Rabbit	PO	0.1-0.2 mg/kg	q12h	Duration: Not established Notes: Use with caution; limited safety data.

Clinical Indications & Species Uses

General Indications

Heart failure
Hypertension
Arrhythmias

Dog (Canine)

Congestive heart failure (especially dilated cardiomyopathy)
Chronic valvular disease with heart failure
Systemic hypertension (adjunctive therapy)
Arrhythmias (e.g., ventricular premature complexes)

Cat (Feline)

Hypertrophic cardiomyopathy (HCM) with heart failure or dynamic outflow tract obstruction
Systemic hypertension (adjunctive therapy)
Arrhythmias

Pharmacology & Mechanism of Action

Drug Class: Beta-blocker (non-selective) with alpha-1 blocking activity | Pharmacological Group: Antihypertensive, antiarrhythmic, cardioprotective agent

Mechanism of Action: Carvedilol is a racemic mixture of non-selective beta-adrenergic receptor antagonist (blocking beta-1 and beta-2 receptors) and alpha-1 adrenergic receptor antagonist. It also possesses antioxidant and anti-apoptotic properties. The beta-blockade reduces heart rate, myocardial contractility, and conduction velocity, thereby decreasing myocardial oxygen demand. Alpha-1 blockade causes vasodilation of peripheral blood vessels, reducing systemic vascular resistance and blood pressure. The combination results in a reduction in cardiac workload and sympathetic tone, which is beneficial in heart failure and hypertension. Additionally, carvedilol inhibits apoptosis and reduces oxidative stress in cardiac tissue, contributing to its cardioprotective effects.

Pharmacodynamics: Carvedilol produces a balanced arterial and venous vasodilation due to alpha-1 blockade, while beta-blockade prevents reflex tachycardia. It reduces heart rate, blood pressure, and myocardial contractility. In heart failure, it improves left ventricular ejection fraction, reduces remodeling, and decreases mortality. It also has anti-ischemic effects and may reduce arrhythmias. The antioxidant effect is due to its carbazole moiety, which scavenges free radicals. The net effect is improved cardiac performance and reduced sympathetic overactivity.

⚡ Pharmacokinetics Summary

Absorption: Carvedilol is well absorbed after oral administration, but undergoes extensive first-pass metabolism in the liver, resulting in an absolute bioavailability of about 25-35% in humans. In dogs, bioavailability is approximately 20-30%. Food can delay absorption but does not significantly affect overall bioavailability.

Distribution: Carvedilol is highly lipophilic and extensively distributed into tissues. It crosses the blood-brain barrier. The volume of distribution is large (about 1.5-2 L/kg in humans). It is highly protein-bound (approximately 95-98%) in plasma.

Metabolism: Carvedilol is extensively metabolized in the liver, primarily by CYP2D6 and CYP2C9 enzymes, with contributions from CYP3A4. It undergoes aromatic ring oxidation and glucuronidation. The metabolites include active metabolites, but they are less potent than the parent drug. The stereoisomers have different metabolic pathways: S(-)-carvedilol is metabolized mainly by CYP2D6, while R(+)-carvedilol is metabolized by CYP2C9 and CYP3A4.

Excretion: Carvedilol is excreted primarily in the feces via bile, with about 60-75% of the dose eliminated in feces and 15-20% in urine. Less than 2% of the drug is excreted unchanged in urine. The elimination half-life is approximately 7-10 hours in humans, but in dogs it is shorter, around 4-6 hours.

Half-Life: Dogs: 4-6 hours; Cats: not well documented, but likely similar to dogs; Horses: not well studied; Humans: 7-10 hours.

Bioavailability: Oral bioavailability is about 20-30% in dogs due to first-pass metabolism; in cats, it may be similar or slightly higher.

Protein Binding: Approximately 95-98% bound to plasma proteins.

Available Formulations & Strengths

Oral Tablet 3.125 mg, 6.25 mg, 12.5 mg, 25 mg (PO)

Oral Extended-Release Capsule 10 mg, 20 mg, 40 mg, 80 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to carvedilol or any component
Sinus bradycardia (heart rate < 50 bpm in dogs)
Second or third-degree atrioventricular block
Cardiogenic shock
Decompensated heart failure (unless stabilized)
Severe hepatic impairment
Bronchospastic disease (e.g., asthma, COPD) - use with extreme caution

Warnings & Clinical Precautions:

Use with caution in patients with diabetes mellitus as beta-blockers may mask signs of hypoglycemia
May mask signs of hyperthyroidism (e.g., tachycardia)
Use with caution in patients with peripheral vascular disease
Abrupt withdrawal may exacerbate angina or heart failure; taper dose gradually
Monitor renal function in patients with renal impairment
Use with caution in patients with a history of anaphylaxis; beta-blockade may increase sensitivity to allergens and reduce response to epinephrine
In cats, use with caution in those with asthma or chronic respiratory disease
May cause hypotension, especially during initial titration
Use with caution in animals with pheochromocytoma (should be used with alpha-blockade first)

Adverse Effects & Reactions

Common:

Hypotension
Bradycardia
Lethargy
Gastrointestinal upset (vomiting, diarrhea)
Dizziness or weakness

Serious / Severe:

Worsening of heart failure
Atrioventricular block
Bronchospasm
Hypoglycemia (especially in diabetics)
Renal impairment

Rare:

Hepatotoxicity
Paresthesia
Depression
Alopecia

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Digoxin	Increased risk of bradycardia and AV block; monitor heart rate and digoxin levels	Moderate
Amiodarone	Additive negative chronotropic and dromotropic effects; increased risk of bradycardia and AV block	High
Calcium channel blockers (e.g., diltiazem, verapamil)	Additive negative inotropic and chronotropic effects; risk of severe hypotension and heart failure	High
Other beta-blockers (e.g., atenolol)	Additive beta-blockade; increased risk of bradycardia and hypotension	Moderate
Cimetidine	May increase carvedilol levels by inhibiting metabolism; monitor for enhanced effects	Moderate
Fluoxetine, paroxetine (CYP2D6 inhibitors)	May increase carvedilol levels; monitor for bradycardia and hypotension	Moderate
NSAIDs (e.g., carprofen)	May reduce antihypertensive effect; monitor blood pressure	Mild
Insulin or oral hypoglycemics	May potentiate hypoglycemic effect and mask signs of hypoglycemia	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Severe bradycardia
Hypotension
Heart block
Cardiogenic shock
Bronchospasm
Hypoglycemia
Seizures (in severe cases)

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Induce emesis if recent ingestion and animal is conscious. Administer activated charcoal to reduce absorption. Provide intravenous fluids for hypotension. Atropine may be used for bradycardia. Glucagon may be used to counteract beta-blockade effects (positive inotropic and chronotropic). In severe cases, use inotropic agents (e.g., dobutamine) and consider temporary cardiac pacing. Monitor blood glucose and treat hypoglycemia with dextrose. Bronchospasm may be treated with beta-agonists (e.g., albuterol) but use with caution due to alpha-blockade.

Food Animal Withdrawal Times

Not approved for food animals; no withdrawal times established. Use in food animals is off-label and prohibited in some jurisdictions.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C, 68-77°F)

Handling & Special Conditions: Protect from moisture; keep in a tightly closed container.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use. Used extra-label in veterinary medicine.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is prohibited under AMDUCA if there is no approved drug for that species/indication. Carvedilol is not approved for veterinary use in food animals; therefore, its use in food animals is not permitted. In companion animals, extra-label use is allowed under the veterinary-client-patient relationship.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Carvedilol is a third-generation beta-blocker with additional alpha-1 blocking and antioxidant properties. In veterinary medicine, it is primarily used in dogs for congestive heart failure, especially dilated cardiomyopathy, and in cats for hypertrophic cardiomyopathy. It is important to initiate therapy at low doses and titrate slowly to avoid exacerbation of heart failure. Regular monitoring of heart rate, blood pressure, and clinical signs is essential. Carvedilol should not be used in animals with decompensated heart failure or significant bradyarrhythmias. It may be used in combination with other cardiac medications such as ACE inhibitors, diuretics, and pimobendan, but careful monitoring for interactions is required. Due to its beta-2 blocking effects, it should be used with caution in animals with reactive airway disease. Overall, carvedilol is a valuable addition to the therapeutic armamentarium for chronic heart failure in companion animals, but its use requires careful patient selection and monitoring.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)